Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) represented a move of 0 percent or $0.21 per share and closed its previous day trading session at $6.37. 0 Shares were traded in the last trading session with an Average Volume of 121.17 Million Shares. The stock currently has a Market Capitalization of 155.43 Million.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
The stock traded between $ 5.49 and $23.97 over 1-Year time period showing its price to sales ratio of 3.9. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-24.8 and 200-Day Simple Moving Average of $-33.12. Its Price to Free Cash Flow is 0 and Price to Book of 1.18.
Analyst’s recommended the stock as 1.7 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) reported its Actual EPS of $-0.38/share. The analysts offering Earnings Estimates for the company were believing that Protagonist Therapeutics, Inc. could bring EPS of $-0.37/share. The difference between Actual EPS and Estimated EPS was -0.01 Percent. Thus showing an Earnings Surprise of -2.7 Percent.
MEI Pharma, Inc. (NASDAQ:MEIP)
In the last trading session, MEI Pharma, Inc. (NASDAQ:MEIP) added its value by 0% closing at the price of $2.8. The stock currently has market capitalization of 198.44 Million, with average volume of 325.04 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently MEI Pharma, Inc. (NASDAQ:MEIP) is showing beta of 2.19. This particular value of beta suggests that MEI Pharma, Inc. (NASDAQ:MEIP) has historically moved 219% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for MEI Pharma, Inc. (NASDAQ:MEIP) is at $-0.89.
The stock currently has RSI of 40.55. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego.
MEI Pharma, Inc. (NASDAQ:MEIP) topped its 52-week high price of $5.14 on 06/06/18 and 52-Week Low Price of $1.79 on 12/21/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 10.78% and monthly volatility of 7.74% respectively.